Advertisement Gullapalli Prasanna, Author at Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by Gullapalli Prasanna

FDA grants IND clearance for RiboX’s RXRG001

Dubbed SPRINX-1 Study, the trial aims to assess the safety and efficacy of RXRG001 in treating radiation-induced xerostomia (RIX) [dry mouth] and hyposalivation conditions. A proprietary product created

Lyell signs agreement to acquire ImmPACT Bio

The acquisition will include ImmPACT’s lead product, IMPT-314, aimed at treating haematologic malignancies, such as large B-cell lymphoma. IMPT-314 is a dual-targeting CAR T-cell product candidate that is